Research on value of different administration models of tiotropium bromide applied to treat asthma combined with COPD / 中国生化药物杂志

ABSTRACT

Objective To explore clinical value of different administration modes applied to treat the asthma combined with chronic obstructive pulmonary disease ( COPD ) .Methods Clinical data of 180 patients with bronchial asthma combined with COPD admitted by the department of respiratory medicine of the Hospital from June 2013 to June 2015 were retrospectively analyzed, and such patients were divided into three groups including 58 patients in the control group, 60 patients in the observation group A and 62 patients in observation group B ( n =62 ) in random cross double-blind method.The patients in the control group were administered and treated with placebo ( once in the morning and at night daily respectively) , the patients in the observation group A were administered and treated with 2.5 μg of tiotropium bromide ( once in the morning and at night daily respectively), and the patients in the observation group B were treated with 2.5 μg of tiotropium bromide (once at night daily respectively), and the treatment efficacy on three groups of patients were observed.Results Average questionnaire scores of FEV1, AUC0 ~24 h , FEV1(0 ~24 h) peak valley value, PEFam , PEFpm , FEV1 and ACQ -7 in 24 hours of patients in the observation group A and observation group B, there were no statistically significant differences between two groups;Questionnaire scores of FEV1, AUC0 ~24 h , FEV1(0 ~24 h) peak valley value, PEFam , PEFpm , FEV1 and ACQ-7 in 24 hours of patients in the observation group A and observation group B were significantly higher than such indexes of patients in the control group, and the differences were statistically significant ( P <0.05 ) .Conclusion Two different dosage regimens of tiotropium bromide with daily dose of 5 μg can significantly keep the bronchus expanding for 24 h, and delivers significant efficacy on the asthma combined with COPD treatment.